Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
OPERATING ACTIVITIES:
Net loss	$ (11,858,000)	$ (5,702,000)
Adjustments to reconcile net loss to net cash (used for) provided by operating activities:
Depreciation, amortization and other	17,597,000	17,537,000
Stock-based compensation expense	5,820,000	5,713,000
Amortization of debt discount and deferred issuance costs	4,266,000	4,232,000
Change in deferred tax assets and liabilities	(7,375,000)	(6,368,000)
Change in fair value of acquisition contingencies	(600,000.0)	0
Gain on extinguishment of Convertible Senior Notes	(421,000)	0
Changes in assets and liabilities:
Accounts receivable	(7,464,000)	3,441,000
Inventories	3,544,000	186,000
Income taxes receivable	(248,000)	234,000
Prepaid expenses and other current and non-current assets	(1,047,000)	(305,000)
Restricted cash	63,000	1,317,000
Accounts payable	984,000	(1,947,000)
Accrued payroll and related expenses	(1,867,000)	772,000
Income taxes payable	(12,000)	729,000
Deferred grant revenue	(3,658,000)	(813,000)
Other current and non-current liabilities	(2,541,000)	1,226,000
Net cash (used for) provided by operating activities:	(4,806,000)	20,252,000
INVESTING ACTIVITIES:
Acquisitions of property, equipment and intangibles	(7,860,000)	(12,003,000)
Acquisition of Immutopics, net of cash acquired	(5,061,000)	0
Net cash used for investing activities:	(12,921,000)	(12,003,000)
FINANCING ACTIVITIES:
Payments on lease obligation	(433,000)	(375,000)
Repurchases of common stock	(20,096,000)	(27,617,000)
Repurchases of Convertible Senior Notes	(4,459,000)	0
Proceeds from issuance of common stock	4,821,000	2,152,000
Payments of debt issuance costs	0	(365,000)
Payments on acquisition contingencies	(207,000)	(129,000)
Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed	0	(229,000)
Net cash used for financing activities:	(20,374,000)	(26,563,000)
Effect of exchange rates on cash	(7,000)	(21,000)
Net decrease in cash and cash equivalents	(38,108,000)	(18,335,000)
Cash and cash equivalents, beginning of period	191,471,000	200,895,000
Cash and cash equivalents, end of period	153,363,000	182,560,000
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for interest	3,331,000	3,744,000
Cash paid for income taxes	459,000	1,920,000
NON-CASH INVESTING ACTIVITIES:
Purchase of property, equipment and intangibles by incurring current liabilities	1,866,000	1,433,000
NON-CASH FINANCING ACTIVITIES:
Reduction of other current liabilities upon issuance of restricted share units	539,000	$ 408,000
Senior 3 Point 25 Percent Convertible Notes Due 2020 [Member] | Convertible Debt [Member]
FINANCING ACTIVITIES:
Repurchases of Convertible Senior Notes	$ (4,500,000)